Garry Beran
AstraZeneca (United Kingdom)(GB)Bioscience Research(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Protein Degradation and Inhibitors, Computational Drug Discovery Methods
Most-Cited Works
- → Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models(2015)294 cited
- → Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)(2010)261 cited
- → Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines(2012)257 cited
- → The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models(2015)79 cited
- → Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers(2016)43 cited
- → Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation(2016)37 cited
- → Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma(2013)25 cited
- → Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib(2009)21 cited
- → Abstract 5365: Molecular and pharmacological (EGFRi, MEKi) characterisation of a colorectal cancer (CRC) cell line panel to evaluate cellular phenotype and efficacy of targeted therapies in CRC(2011)7 cited
- → Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC(2014)6 cited